Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants

NCT03876301 · clinicaltrials.gov ↗

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Blood Coagulation Disorder
Blood Coagulation Disorders, Inherited
Coagulation Protein Disorders
Hemophilia A
Genetic Diseases, Inborn
Genetic Diseases, X-Linked
Hematologic Diseases
Hemorrhagic Disorders
Factor VIII Deficiency

Interventions

DRUG: Standard of Care FVIII Replacement therapy

Sponsor

Spark Therapeutics, Inc.